AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23631443 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE)
Number of subjects: 13
Study 23631443 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 13
Study 23631443 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of metformin and RE
Number of subjects: 13
Study 21823379 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIPA (n = 20)
Number of subjects: 40
Study 21823379 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube group (n = 20)
Number of subjects: 40
Study 19205723 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise (AE; n = 15)
Number of subjects: 46
Study 19205723 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic bands (EB; n = 21)
Number of subjects: 46
Study 19205723 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 10)
Number of subjects: 46
Study 17284576 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine, 30-40 mg, twice a day for 1 month
Number of subjects: 16
Study 17284576 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 16
Study 15945304 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsplinted implants
Number of subjects: 18
Study 15945304 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinted implants
Number of subjects: 18
Study 15945304 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinted bar-retained method
Number of subjects: 18
Study 15945304 — intervention group
Group type: COMPARATOR
Intervention: Unsplinted prosthodontic method
Number of subjects: 18
Study 12823645 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg day‐1
Number of subjects: 56
Study 12823645 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (CEE) 0.625 mg day‐1
Number of subjects: 56
Study 12823645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 10195186 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation administered after learning
Number of subjects: 0
Study 10195186 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8585003 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU antiXa/kg of Dalteparin (Fragmin) injected at 8 p.m.
Number of subjects: 10
Study 8585003 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU antiXa/kg of Dalteparin (Fragmin) injected at 8 a.m.
Number of subjects: 10
Study 8585003 — intervention group
Group type: COMPARATOR
Intervention: Control cycle without injection
Number of subjects: 10
Study 2146058 — intervention group
Group type: EXPERIMENTAL
Intervention: ritanserin
Number of subjects: 8
Study 2146058 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 304984 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of dextran 60 intraoperatively (group A)
Number of subjects: 91
Study 304984 — intervention group
Group type: COMPARATOR
Intervention: 100 ml dextran 60 on days 1 to 5 after operation (group B)
Number of subjects: 91
Study 31668468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 286
Study 31668468 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 286
Study 29813176 — intervention group
Group type: EXPERIMENTAL
Intervention: Female drivers who frequently use phones for texting/answering calls; less favorable attitudes towards safety; highly disinhibited individuals.
Number of subjects: 447
Study 29813176 — intervention group
Group type: EXPERIMENTAL
Intervention: More years with a valid driving license; self-efficacy toward self-regulation in demanding traffic conditions; police enforcement; texting tasks; demanding traffic conditions.
Number of subjects: 447
Study 27803024 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex 11
Number of subjects: 20
Study 27803024 — intervention group
Group type: COMPARATOR
Intervention: SBAR
Number of subjects: 20
Study 24561771 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Benifuuki' green tea containing O‐methylated EGCG
Number of subjects: 51
Study 24561771 — intervention group
Group type: COMPARATOR
Intervention: 'Yabukita' green tea (placebo)
Number of subjects: 51
Study 22555112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monthly treatment
Number of subjects: 1107
Study 22555112 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab monthly treatment
Number of subjects: 1107
Study 22555112 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly treatment
Number of subjects: 1107
Study 22555112 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed treatment
Number of subjects: 1107
Study 22555112 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from monthly to as-needed treatment
Number of subjects: 1107
Study 22555112 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 1107
Study 22555112 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 1107
Study 20395648 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 20395648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18547128 — intervention group
Group type: COMPARATOR
Intervention: IR methylphenidate (Rubifen) 52.1 mg (SD = 13.8 mg) three times daily for 3 months
Number of subjects: 70
Study 18547128 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (Concerta) 57.9 mg (SD = 16.5 mg) once daily after switch
Number of subjects: 70
Study 16177676 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol treatment (Group I, n=32)
Number of subjects: 59
Study 16177676 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Group II, n=27)
Number of subjects: 59
Study 11901392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone injection into the tendon sheath
Number of subjects: 18
Study 11901392 — intervention group
Group type: COMPARATOR
Intervention: Thumb spica splints
Number of subjects: 18
Study 10413387 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program for chronic disease (6 months duration)
Number of subjects: 952
Study 10413387 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 952
Study 7768585 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium 10 mg
Number of subjects: 576
Study 7768585 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium 25 mg
Number of subjects: 576
Study 7768585 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium 50 mg
Number of subjects: 576
Study 7768585 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium 100 mg
Number of subjects: 576
Study 7768585 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium 150 mg
Number of subjects: 576
Study 7768585 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate 20 mg
Number of subjects: 576
Study 7768585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 2186523 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C group (CsA discontinued, maintained on Aza and prednisone)
Number of subjects: 92
Study 2186523 — intervention group
Group type: EXPERIMENTAL
Intervention: TD group (Aza added to continued low-dose CsA and prednisone)
Number of subjects: 92
Study 2186523 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C group
Number of subjects: 92
Study 2186523 — intervention group
Group type: EXPERIMENTAL
Intervention: TD group
Number of subjects: 92
Study 2186523 — intervention group
Group type: EXPERIMENTAL
Intervention: TD regimen
Number of subjects: 92
Study 508705 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake at adequate energy intake (418 kJ/kg body‐weight)
Number of subjects: 4
Study 508705 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake at decreased energy intake (334 kJ/kg body‐weight)
Number of subjects: 4
Study 31323175 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic lead placement (AP)
Number of subjects: 270
Study 31323175 — intervention group
Group type: COMPARATOR
Intervention: Paresthesia-mapped lead placement (PM)
Number of subjects: 270
Study 31323175 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 270
Study 31141954 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high-protein (MHP) diet
Number of subjects: 305
Study 31141954 — intervention group
Group type: COMPARATOR
Intervention: Low-fat (LF) diet
Number of subjects: 305
Study 27903841 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Program (EP)
Number of subjects: 6
Study 27903841 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 6
Study 26478867 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (n = 10)
Number of subjects: 39
Study 26478867 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 39
Study 23589814 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music interventions (lullaby and rhythm)
Number of subjects: 272
Study 23589814 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm sound interventions
Number of subjects: 272
Study 23589814 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrained breath sounds
Number of subjects: 272
Study 23589814 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-preferred lullabies
Number of subjects: 272
Study 23589814 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 272
Study 21323289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 24 mg plus morphine 8 mg (group R+M)
Number of subjects: 156
Study 21323289 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group N/S)
Number of subjects: 156
Study 21323289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 40 mg (group R)
Number of subjects: 156
Study 21323289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 36 mg plus ketoprofen 100 mg (group R+K)
Number of subjects: 156
Study 18954999 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 77
Study 17096305 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention by specially trained primary care physicians
Number of subjects: 84
Study 17096305 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 84
Study 17096305 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention
Number of subjects: 84
Study 17096305 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of patients with marked preference for SDM
Number of subjects: 84
Study 15273003 — intervention group
Group type: EXPERIMENTAL
Intervention: Group condition with fellow ingroup members present
Number of subjects: 0
Study 10740573 — intervention group
Group type: EXPERIMENTAL
Intervention: Larva therapy (LT)
Number of subjects: 70
Study 9193008 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 9193008 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and ASA interaction
Number of subjects: 0
Study 9193008 — intervention group
Group type: COMPARATOR
Intervention: Patients taking ASA
Number of subjects: 0
Study 1441873 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 5 mg (Group 2)
Number of subjects: 100
Study 1441873 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group 1)
Number of subjects: 100
Study 4078074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B phototherapy with short-contact anthralin
Number of subjects: 11
Study 4078074 — intervention group
Group type: COMPARATOR
Intervention: Ultraviolet B phototherapy without short-contact anthralin
Number of subjects: 11
Study 31466334 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosylceramide extracted from pineapple (GCP)
Number of subjects: 16
Study 31466334 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 16
Study 29736633 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-child-disease triangle (MCDT) intervention, 10 sessions of 90 minutes each over 7 weeks
Number of subjects: 22
Study 29736633 — intervention group
Group type: COMPARATOR
Intervention: Control group received ten simple conversational sessions as a dummy intervention
Number of subjects: 22
Study 26484869 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 92
Study 26484869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment plus Contingency Management (CBT + CM)
Number of subjects: 92
Study 24397308 — intervention group
Group type: EXPERIMENTAL
Intervention: ECS scheduled at 38(+3) weeks
Number of subjects: 1196
Study 24397308 — intervention group
Group type: COMPARATOR
Intervention: ECS scheduled at 39(+3) weeks
Number of subjects: 1196
Study 23177293 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWD)
Number of subjects: 2054
Study 23177293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPX) - peak oxygen consumption (VO(2))
Number of subjects: 2054
Study 23177293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPX) - ventilatory equivalents for exhaled carbon dioxide (VE/VCO(2) slope)
Number of subjects: 2054
Study 20713145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokishakuyakusan with medicinal cultivar of Paeonia lactiflora (MTS)
Number of subjects: 12
Study 20713145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokishakuyakusan with ornamental cultivar of Paeonia lactiflora (OTS)
Number of subjects: 12
Study 18840266 — intervention group
Group type: EXPERIMENTAL
Intervention: Invited participants (n = 116)
Number of subjects: 355
Study 18840266 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosed with diabetes (n = 6)
Number of subjects: 355
Study 18840266 — intervention group
Group type: COMPARATOR
Intervention: Non-attenders
Number of subjects: 355
Study 18840266 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenders
Number of subjects: 355
Study 16101874 — intervention group
Group type: EXPERIMENTAL
Intervention: Kukui nut oil
Number of subjects: 30
Study 16101874 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil (placebo)
Number of subjects: 30
Study 12572358 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Ca supplementation per day
Number of subjects: 161
Study 12572358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcium supplementation)
Number of subjects: 161
Study 10816273 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromechanical mapping of regional left ventricular function
Number of subjects: 10
Study 8667133 — intervention group
Group type: COMPARATOR
Intervention: Control group, no irrigation
Number of subjects: 6
Study 8667133 — intervention group
Group type: COMPARATOR
Intervention: Saline group, irrigation with 2 cc of 0.85% saline
Number of subjects: 6
Study 8667133 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline group, irrigation with 2 cc of aqueous tetracycline HCl, 50 mg/ml (5%)
Number of subjects: 6
Study 8667133 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine group, irrigation with 2 cc of chlorhexidine
Number of subjects: 6
Study 1536698 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 0
Study 6697280 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational package on hypertension
Number of subjects: 56
Study 6697280 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational package)
Number of subjects: 56
Study 30992093 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-based lifestyle modification treatment
Number of subjects: 6
Study 28629828 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative procedures for proximal femoral bone metastasis (osteosynthetic devices vs. prosthetic replacement)
Number of subjects: 26
Study 28629828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis treatment
Number of subjects: 26
Study 26519020 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (walking and running for 25 minutes twice/week for 10 weeks at intensity corresponding to individual's ventilatory threshold)
Number of subjects: 56
Study 26519020 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary employees before intervention)
Number of subjects: 56
Study 24004475 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based patient activation intervention
Number of subjects: 500
Study 24004475 — intervention group
Group type: COMPARATOR
Intervention: Control condition (preventive services questions)
Number of subjects: 500
Study 21664155 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3% NaOCl
Number of subjects: 30
Study 21664155 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6% NaOCl
Number of subjects: 30
Study 21664155 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl
Number of subjects: 30
Study 21664155 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3% NaOCl and 2.6% NaOCl
Number of subjects: 30
Study 18243407 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (V)
Number of subjects: 65
Study 18243407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus Cisplatin (VP)
Number of subjects: 65
Study 17070148 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab bolus-only
Number of subjects: 0
Study 17070148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17070148 — intervention group
Group type: COMPARATOR
Intervention: Abciximab bolus plus infusion
Number of subjects: 0
Study 12854176 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin/low molecular weight heparin (LMWH) treatment
Number of subjects: 52
Study 12854176 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment
Number of subjects: 52
Study 11043809 — intervention group
Group type: EXPERIMENTAL
Intervention: Kampo kami-shoyo-san (TJ-24)
Number of subjects: 8
Study 9261326 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine 0.5% ophthalmic solution
Number of subjects: 100
Study 9261326 — intervention group
Group type: COMPARATOR
Intervention: control vehicle drops
Number of subjects: 100
Study 8489449 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41 (0.006% solution, approximately 2 micrograms per treatment)
Number of subjects: 15
Study 8489449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3549966 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month educational program provided by a nurse practitioner
Number of subjects: 170
Study 3549966 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170
Study 3549966 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipients with strong social supports
Number of subjects: 170
Study 3549966 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 170
Study 2812914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (80 mg/kg body weight, intramuscularly, once daily for 5 days)
Number of subjects: 59
Study 2812914 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (50 to 100 mg/kg body weight, orally, divided into 4 doses for 3 weeks)
Number of subjects: 59
Study 29574484 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg, once daily)
Number of subjects: 118
Study 29574484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 29027715 — intervention group
Group type: EXPERIMENTAL
Intervention: HE4
Number of subjects: 164
Study 29027715 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125
Number of subjects: 164
Study 29027715 — intervention group
Group type: EXPERIMENTAL
Intervention: ROMA
Number of subjects: 164
Study 29027715 — intervention group
Group type: EXPERIMENTAL
Intervention: CPH‐I
Number of subjects: 164
Study 29027715 — intervention group
Group type: EXPERIMENTAL
Intervention: RMI
Number of subjects: 164
Study 29027715 — intervention group
Group type: EXPERIMENTAL
Intervention: MI
Number of subjects: 164
Study 26605928 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (400 mg vaginal suppositories, twice daily)
Number of subjects: 836
Study 26605928 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched vaginal suppositories)
Number of subjects: 836
Study 23187965 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide (10 mg, subcutaneously administered)
Number of subjects: 36
Study 23187965 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects aged <65 years
Number of subjects: 36
Study 21560157 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal surface electromyography (EMG) during filling and voiding phases
Number of subjects: 655
Study 21560157 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative EMG activity
Number of subjects: 655
Study 21560157 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with neither abdominal straining during void nor interrupted flow
Number of subjects: 655
Study 18478093 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw‐HBV/Hib‐MenAC vaccine
Number of subjects: 280
Study 18478093 — intervention group
Group type: COMPARATOR
Intervention: DTPw‐HBV/Hib vaccine
Number of subjects: 280
Study 16525624 — intervention group
Group type: EXPERIMENTAL
Intervention: Paste zinc oxide‐eugenal
Number of subjects: 283
Study 16525624 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitapex
Number of subjects: 283
Study 15532520 — intervention group
Group type: EXPERIMENTAL
Intervention: Transformational leadership style
Number of subjects: 266
Study 15532520 — intervention group
Group type: COMPARATOR
Intervention: Transactional leadership style
Number of subjects: 266
Study 15532520 — intervention group
Group type: EXPERIMENTAL
Intervention: Private hospitals
Number of subjects: 266
Study 15532520 — intervention group
Group type: COMPARATOR
Intervention: Public hospitals
Number of subjects: 266
Study 11240031 — intervention group
Group type: COMPARATOR
Intervention: Circulating levels of soluble forms of adhesion molecules (sICAM-1 and sVCAM-1)
Number of subjects: 0
Study 11240031 — intervention group
Group type: COMPARATOR
Intervention: Attachment capacities of circulating lymphocytes to rICAM-1 and rVCAM-1
Number of subjects: 0
Study 11240031 — intervention group
Group type: COMPARATOR
Intervention: Fibronectin-penetrating capacities of circulating lymphocytes
Number of subjects: 0
Study 11240031 — intervention group
Group type: COMPARATOR
Intervention: Cellular concentrations of MMP-9 in circulating lymphocytes
Number of subjects: 0